AbbVie (ABBV) Competitors $230.88 +0.19 (+0.08%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$231.18 +0.30 (+0.13%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ABBV vs. AMGN, GILD, MRNA, ABT, BMY, JNJ, LLY, MRK, PFE, and ZTSShould you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), Pfizer (PFE), and Zoetis (ZTS). These companies are all part of the "medical" sector. AbbVie vs. Its Competitors Amgen Gilead Sciences Moderna Abbott Laboratories Bristol Myers Squibb Johnson & Johnson Eli Lilly and Company Merck & Co., Inc. Pfizer Zoetis Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership. Which has more risk & volatility, AMGN or ABBV? Amgen has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Which has higher earnings and valuation, AMGN or ABBV? AbbVie has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmgen$33.42B4.67$4.09B$12.2323.72AbbVie$56.33B7.24$4.28B$2.10109.94 Do analysts recommend AMGN or ABBV? Amgen presently has a consensus price target of $309.42, suggesting a potential upside of 6.65%. AbbVie has a consensus price target of $231.90, suggesting a potential upside of 0.44%. Given Amgen's higher probable upside, analysts plainly believe Amgen is more favorable than AbbVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amgen 1 Sell rating(s) 11 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.35AbbVie 0 Sell rating(s) 9 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 2.79 Is AMGN or ABBV a better dividend stock? Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 2.8%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 312.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and AbbVie has increased its dividend for 53 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and lower payout ratio. Does the media refer more to AMGN or ABBV? In the previous week, AbbVie had 31 more articles in the media than Amgen. MarketBeat recorded 96 mentions for AbbVie and 65 mentions for Amgen. AbbVie's average media sentiment score of 1.31 beat Amgen's score of 1.09 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 42 Very Positive mention(s) 2 Positive mention(s) 12 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive AbbVie 76 Very Positive mention(s) 9 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in AMGN or ABBV? 76.5% of Amgen shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.8% of Amgen shares are owned by insiders. Comparatively, 0.3% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is AMGN or ABBV more profitable? Amgen has a net margin of 18.96% compared to AbbVie's net margin of 6.45%. AbbVie's return on equity of 699.66% beat Amgen's return on equity.Company Net Margins Return on Equity Return on Assets Amgen18.96% 174.71% 13.12% AbbVie 6.45%699.66%13.64% SummaryAbbVie beats Amgen on 13 of the 20 factors compared between the two stocks. Get AbbVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABBV vs. The Competition Export to ExcelMetricAbbVieLarge Cap Pharma IndustryMedical SectorNYSE ExchangeMarket Cap$407.53B$274.61B$6.10B$21.89BDividend Yield2.84%2.56%5.67%3.61%P/E Ratio109.9431.3386.0528.83Price / Sales7.245.23612.1482.97Price / Cash15.4514.7838.5024.17Price / Book121.5219.9012.754.51Net Income$4.28B$8.49B$3.31B$1.01B7 Day Performance-1.36%-2.74%0.80%-3.53%1 Month Performance4.90%2.17%6.21%-1.95%1 Year Performance18.88%-4.36%80.34%10.26% AbbVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABBVAbbVie4.5774 of 5 stars$230.88+0.1%$231.90+0.4%+18.8%$407.53B$56.33B109.9455,000Positive NewsAnalyst ForecastAnalyst RevisionAMGNAmgen4.5537 of 5 stars$294.12-1.3%$309.70+5.3%-9.6%$160.37B$34.92B24.0528,000Positive NewsAnalyst UpgradeAnalyst RevisionGILDGilead Sciences4.856 of 5 stars$113.58+0.8%$117.17+3.2%+38.4%$140.93B$28.75B22.6317,600Trending NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.239 of 5 stars$27.54-3.3%$41.81+51.8%-52.8%$10.72B$3.24B-3.665,800Analyst ForecastABTAbbott Laboratories4.9489 of 5 stars$133.63-0.7%$145.39+8.8%+14.4%$232.58B$43.11B16.75114,000Positive NewsUpcoming EarningsAnalyst ForecastBMYBristol Myers Squibb4.9762 of 5 stars$45.16-0.6%$56.38+24.8%-16.0%$91.92B$47.70B18.2134,100Trending NewsAnalyst RevisionJNJJohnson & Johnson4.6681 of 5 stars$188.23-0.2%$189.12+0.5%+18.8%$453.32B$90.63B20.13138,100Trending NewsUpcoming EarningsAnalyst ForecastLLYEli Lilly and Company4.9964 of 5 stars$845.40+0.7%$938.94+11.1%-8.5%$800.13B$53.26B55.2547,000Trending NewsAnalyst ForecastAnalyst RevisionMRKMerck & Co., Inc.4.9928 of 5 stars$88.83-0.4%$106.41+19.8%-21.4%$221.88B$64.17B13.6975,000Trending NewsAnalyst ForecastAnalyst RevisionPFEPfizer4.9554 of 5 stars$26.45-3.4%$28.41+7.4%-15.5%$150.38B$63.83B14.0781,000Trending NewsDividend AnnouncementAnalyst ForecastOptions VolumeAnalyst RevisionZTSZoetis4.8222 of 5 stars$145.39-0.7%$200.88+38.2%-25.9%$64.43B$9.26B25.0213,800Positive NewsDividend AnnouncementAnalyst Forecast Related Companies and Tools Related Companies AMGN Competitors GILD Competitors MRNA Competitors ABT Competitors BMY Competitors JNJ Competitors LLY Competitors MRK Competitors PFE Competitors ZTS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ABBV) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbbVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbbVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
